Nova Agritech Limited has announced its unaudited financial results for the quarter ended December 31, 2025, showing mixed performance across standalone and consolidated operations. The company, engaged in manufacturing, marketing and distribution of soil health management, crop nutrition and crop protection products, reported the results following a Board meeting held on February 12, 2026.

Standalone Financial Performance

The company's standalone operations showed a decline in revenue during the quarter. Key financial metrics demonstrate the challenging operating environment faced by the company.

For the nine months ended December 31, 2025, standalone revenue was ₹5,743.83 lakhs compared to ₹11,143.67 lakhs in the corresponding period of the previous year. Net profit for the nine-month period stood at ₹356.89 lakhs versus ₹1,007.21 lakhs in the previous year.

Consolidated Financial Results

The consolidated results, which include wholly owned subsidiaries Nova Agri Sciences Private Limited and Nova Agri Seeds Private Limited, also reflected similar trends with revenue declining year-over-year.

For the nine months ended December 31, 2025, consolidated revenue was ₹20,567.99 lakhs against ₹21,279.12 lakhs in the previous year, while net profit was ₹1,261.80 lakhs compared to ₹2,160.98 lakhs.

Operational Highlights

The company's cost structure showed some variations during the quarter. Cost of raw materials consumed on a standalone basis was ₹1,652.97 lakhs in Q3FY26 compared to ₹2,788.80 lakhs in Q3FY25. Employee benefits expense increased to ₹340.73 lakhs from ₹320.57 lakhs year-over-year.

On the consolidated front, cost of raw materials consumed was ₹5,365.13 lakhs versus ₹8,270.90 lakhs in the previous year quarter. The company benefited from positive changes in inventories of finished goods and work-in-progress, which contributed ₹786.05 lakhs to profitability in Q3FY26.

Corporate Governance and Compliance

The financial results were reviewed by the company's Audit Committee and approved by the Board of Directors. Independent auditors NSVR & Associates LLP conducted a limited review of both standalone and consolidated results as required under SEBI regulations.

The company confirmed that complete IPO proceeds were utilized as of September 30, 2025, and no statement of deviation or variation in IPO fund utilization was required for the current quarter. The paid-up equity share capital remained unchanged at ₹1,850.40 lakhs with a face value of ₹2 per share.

Nova Agritech has received a license amendment from the Telangana Government that authorizes the company to manufacture biostimulants at its formulation plant. This regulatory approval marks an important milestone for the agricultural company as it expands its manufacturing capabilities.

License Amendment Details

The license amendment specifically enables Nova Agritech to produce biostimulants at its existing formulation plant facility. This approval from the Telangana Government provides the necessary regulatory framework for the company to enter the biostimulants manufacturing segment.

Product Range Expansion

The license amendment enables Nova Agritech to expand its product range by adding biostimulants to its manufacturing portfolio. This diversification allows the company to broaden its offerings in the agricultural inputs sector and potentially serve a wider customer base.

Biostimulants represent a growing segment in the agricultural industry, and this regulatory approval positions Nova Agritech to participate in this market. The company can now leverage its existing formulation plant infrastructure to manufacture these specialized agricultural products.

Manufacturing Capabilities

With the license amendment in place, Nova Agritech can utilize its formulation plant to produce biostimulants alongside its existing product lines. This development enhances the company's manufacturing flexibility and allows for better utilization of its production facilities.

The regulatory approval demonstrates Nova Agritech's compliance with government standards and requirements for biostimulants production, providing a foundation for the company's expansion into this product category.